<bill session="116" type="h" number="7722" updated="2023-01-11T13:45:52Z">
  <state datetime="2020-07-22">REFERRED</state>
  <status>
    <introduced datetime="2020-07-22"/>
  </status>
  <introduced datetime="2020-07-22"/>
  <titles>
    <title type="display">Matt&#226;&#8364;&#8482;s Act</title>
    <title type="short" as="introduced">Matt&#226;&#8364;&#8482;s Act</title>
    <title type="official" as="introduced">To limit the price of insulin drugs accessible for participants, beneficiaries, and enrollees enrolled in group or individual health insurance coverage and group health plans and for uninsured individuals who have diabetes, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="F000449"/>
  <cosponsors>
    <cosponsor bioguide_id="C001119" joined="2020-07-22"/>
  </cosponsors>
  <actions>
    <action datetime="2020-07-22">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-07-22" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2020-07-22">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSED" name="House Education and the Workforce" subcommittee="" activity="Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Business records"/>
    <term name="Congressional oversight"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug therapy"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Inflation and prices"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2022-04-18T15:43:03Z" status="Introduced in House">Matt's Act

This bill limits the amount that private health insurance plans may charge plan holders for insulin drugs to a maximum of $20, or $0 for high deductible plans; pharmacies may charge an uninsured individual who has diabetes the average net price of such drugs after deducting any rebates and discounts provided by drug manufacturers, plus limited additional charges for distributing and dispensing costs.</summary>
</bill>
